MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
Condition: Plexiform Neurofibroma · Neurofibromatosis Type 1 (NF1) · Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
About this study
This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants will receive mirdametinib (PD-0325901). Eligible participants may continue in a long-term follow-up phase.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (43)
| University of Alabama at Birmingham/Children's of Alabama | Birmingham, Alabama, United States | — |
| Mayo Clinic Arizona | Phoenix, Arizona, United States | — |
| Arkansas Children's Hospital | Little Rock, Arkansas, United States | — |
| Children's Hospital Los Angeles | Los Angeles, California, United States | — |
| University of California, Los Angeles (UCLA) | Los Angeles, California, United States | — |
| Children's Hospital of Orange County | Orange, California, United States | — |
| University of California - Irvine Health | Orange, California, United States | — |
| Lucile Packard Children's Hospital Stanford | Palo Alto, California, United States | — |
| University of California - Davis | Sacramento, California, United States | — |
| Children's Hospital Colorado | Aurora, Colorado, United States | — |
| Nemours A. I. duPont Hospital for Children | Wilmington, Delaware, United States | — |
| Children's National Hospital | Washington D.C., District of Columbia, United States | — |
+ 31 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03962543